Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - American Depositary Shares
(NQ:
ASND
)
221.88
-1.94 (-0.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma A/S - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
What's Driving the Market Sentiment Around Ascendis Pharma?
↗
August 04, 2025
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
↗
July 28, 2025
Via
Benzinga
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
↗
July 22, 2025
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
↗
July 07, 2025
Via
Benzinga
Peering Into Ascendis Pharma's Recent Short Interest
↗
July 03, 2025
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
↗
June 12, 2025
Via
Benzinga
Is Ascendis Pharma Gaining or Losing Market Support?
↗
June 03, 2025
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
↗
May 29, 2025
Via
Benzinga
Earnings Scheduled For May 1, 2025
↗
May 01, 2025
Via
Benzinga
A Glimpse of Ascendis Pharma's Earnings Potential
↗
April 30, 2025
Via
Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
↗
May 21, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
↗
May 06, 2025
Via
Benzinga
This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
↗
May 05, 2025
Via
Benzinga
Why ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) could fit Mark Minervini’s high-growth criteria
↗
April 28, 2025
A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing?
Via
Chartmill
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
↗
April 15, 2025
Via
Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
↗
March 04, 2025
Via
Benzinga
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
↗
February 19, 2025
Via
Benzinga
Earnings Scheduled For February 12, 2025
↗
February 12, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
↗
January 23, 2025
Via
Benzinga
Does ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) show the characteristics of a Minervini super stock?
↗
April 04, 2025
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).
Via
Chartmill
Looking Into Ascendis Pharma's Recent Short Interest
↗
March 26, 2025
Via
Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
↗
March 25, 2025
Via
Benzinga
Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) a Minervini-style stock?
↗
March 14, 2025
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).
Via
Chartmill
Why Is BioMarin Stock Trading Higher On Thursday?
↗
February 20, 2025
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.
Via
Benzinga
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
↗
February 13, 2025
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.
Via
Benzinga
Looking Into Ascendis Pharma's Recent Short Interest
↗
January 15, 2025
Via
Benzinga
Peering Into Ascendis Pharma's Recent Short Interest
↗
December 03, 2024
Via
Benzinga
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing
↗
February 13, 2025
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.
Via
Stocktwits
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
January 07, 2025
Via
Benzinga
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
November 22, 2024
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
